Quince Therapeutics receives Nasdaq delisting notice after negative stockholders' equity

Quince Therapeutics, Inc.

On Aug 31, 2026, Nasdaq notified QNCX that stockholders' equity was ($35.3M) as of June 30, 2026, below $10M minimum.
Company has until Oct 15, 2026 to submit compliance plan; Nasdaq may grant extension to Feb 27, 2027.
Shares continue trading on Nasdaq Global Select under QNCX; no immediate delisting effect.
Filed initial listing application to move to Nasdaq Capital Market; may rename to IRulya Therapeutics Inc. under IRLA.
Management evaluating alternatives; no assurance of regaining compliance or listing approval.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.